open access

Vol 89, No 5 (2018)
ORIGINAL PAPERS Gynecology
Published online: 2018-05-30
Get Citation

Predictors of IVF/ICSI success following treatment of endometriosis as the cause of primary infertility

Jovan S. Bila, Snezana Vidakovic, Svetlana Spremovic Radjenovic, Milan Dokic, Lela Surlan, Radmila Sparic
DOI: 10.5603/GP.a2018.0042
·
Pubmed: 30084475
·
Ginekol Pol 2018;89(5):240-248.

open access

Vol 89, No 5 (2018)
ORIGINAL PAPERS Gynecology
Published online: 2018-05-30

Abstract

Objectives: Treatment of endometriosis prior to IVF/ICSI could be followed by the significant reduction of ovarian reserve. The aim is to identify potential markers of the IVF/ICSI outcome in patients with endometriosis associated infertility and to evaluate their clinical significance.

Material and methods: The prospective cohort study included 73 patients with primary infertility caused by endometriosis that were subjected to 77 IVF/ICSI cycles. Patients were classified into two groups. In the first group some type of treatment had previously been applied, and in the second group patients were immediately subjected to the IVF/ICSI procedures.

Results: When pregnancy was achieved, there were significantly more patients under 35 years of age, more patients with primary infertility duration up to 3 years, and more patients with endometriosis that was previously treated (77.4%) (p < 0.039). In the cases of the successful outcome Endometriosis Fertility Index > 7, lower basal FSH and FSH/LH ratio were found, as well as significantly higher basal E2, basal P4 and AMH. Significantly lower doses of gonadotropins were needed in cases of the successful outcome, and long protocol with agonists was more frequently used. Multivariate logistic regres­sion analysis showed that previous therapy of endometriosis, P4 ≥ 0.7 ng/mL, AMH ≥ 0.9 ng/mL, A class of embryos, and the use of long protocol with agonists were predictors of the successful IVF/ICSI outcome.

Conclusions: Therapy for endometriosis, AMH and P4 levels appeared to be predictors for the successful IVF/ICSI outcome and the use of long protocol with agonists could be advised in these cycles.

Abstract

Objectives: Treatment of endometriosis prior to IVF/ICSI could be followed by the significant reduction of ovarian reserve. The aim is to identify potential markers of the IVF/ICSI outcome in patients with endometriosis associated infertility and to evaluate their clinical significance.

Material and methods: The prospective cohort study included 73 patients with primary infertility caused by endometriosis that were subjected to 77 IVF/ICSI cycles. Patients were classified into two groups. In the first group some type of treatment had previously been applied, and in the second group patients were immediately subjected to the IVF/ICSI procedures.

Results: When pregnancy was achieved, there were significantly more patients under 35 years of age, more patients with primary infertility duration up to 3 years, and more patients with endometriosis that was previously treated (77.4%) (p < 0.039). In the cases of the successful outcome Endometriosis Fertility Index > 7, lower basal FSH and FSH/LH ratio were found, as well as significantly higher basal E2, basal P4 and AMH. Significantly lower doses of gonadotropins were needed in cases of the successful outcome, and long protocol with agonists was more frequently used. Multivariate logistic regres­sion analysis showed that previous therapy of endometriosis, P4 ≥ 0.7 ng/mL, AMH ≥ 0.9 ng/mL, A class of embryos, and the use of long protocol with agonists were predictors of the successful IVF/ICSI outcome.

Conclusions: Therapy for endometriosis, AMH and P4 levels appeared to be predictors for the successful IVF/ICSI outcome and the use of long protocol with agonists could be advised in these cycles.

Get Citation

Keywords

endometriosis, IVF/ICSI, ovarian reserve, AMH, long protocol

Supplementary Files (2)
Title page
Download
13KB
Cover letter
Download
14KB
About this article
Title

Predictors of IVF/ICSI success following treatment of endometriosis as the cause of primary infertility

Journal

Ginekologia Polska

Issue

Vol 89, No 5 (2018)

Pages

240-248

Published online

2018-05-30

DOI

10.5603/GP.a2018.0042

Pubmed

30084475

Bibliographic record

Ginekol Pol 2018;89(5):240-248.

Keywords

endometriosis
IVF/ICSI
ovarian reserve
AMH
long protocol

Authors

Jovan S. Bila
Snezana Vidakovic
Svetlana Spremovic Radjenovic
Milan Dokic
Lela Surlan
Radmila Sparic

References (33)
  1. Kokcu A. Possible effects of endometriosis-related immune events on reproductive function. Arch Gynecol Obstet. 2013; 287(6): 1225–1233.
  2. Sanchez AM, Vanni VS, Bartiromo L, et al. Is the oocyte quality affected by endometriosis? A review of the literature. J Ovarian Res. 2017; 10(1): 43.
  3. Menezo YJR, Silvestris E, Dale B, et al. Oxidative stress and alterations in DNA methylation: two sides of the same coin in reproduction. Reprod Biomed Online. 2016; 33(6): 668–683.
  4. Schleedoorn MJ, Nelen WL, Dunselman GAJ, et al. EndoKey Group, European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014; 29(3): 400–412.
  5. Practice Committee of the American Society for Reproductive Medicine. Endometriosis and infertility: a committee opinion. Fertil Steril. 2012; 98(3): 591–598.
  6. Yoo JiH, Cha SH, Park CW, et al. Serum anti-Müllerian hormone is a better predictor of ovarian response than FSH and age in IVF patients with endometriosis. Clin Exp Reprod Med. 2011; 38(4): 222–227.
  7. Nelson SM, Yates RW, Lyall H, et al. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod. 2009; 24(4): 867–875.
  8. Broer SL, Broekmans FJM, Laven JSE, et al. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014; 20(5): 688–701.
  9. Adamson GD, Pasta DJ. Endometriosis fertility index: the new, validated endometriosis staging system. Fertil Steril. 2010; 94(5): 1609–1615.
  10. Shahrokh Tehraninezhad E, Mehrabi F, Taati R, et al. Analysis of ovarian reserve markers (AMH, FSH, AFC) in different age strata in IVF/ICSI patients. Int J Reprod Biomed (Yazd). 2016; 14(8): 501–506.
  11. Barbakadze L, Kristesashvili J, Khonelidze N, et al. The correlations of anti-mullerian hormone, follicle-stimulating hormone and antral follicle count in different age groups of infertile women. Int J Fertil Steril. 2015; 8(4): 393–398.
  12. Somigliana E, Berlanda N, Benaglia L, et al. Surgical excision of endometriomas and ovarian reserve: a systematic review on serum antimüllerian hormone level modifications. Fertil Steril. 2012; 98(6): 1531–1538.
  13. Chen Y, Pei H, Chang Y, et al. The impact of endometrioma and laparoscopic cystectomy on ovarian reserve and the exploration of related factors assessed by serum anti-Mullerian hormone: a prospective cohort study. J Ovarian Res. 2014; 7: 108.
  14. Luca A, Nemescu D, Butnaru M, et al. Ovarian stimulation outcome in infertile women with endometriosis undergoing IVF. Ginekol Pol. 2016; 87(1): 37–41.
  15. Seckin B, Turkcapar F, Ozaksit G. Elevated day 3 FSH/LH ratio: a marker to predict IVF outcome in young and older women. J Assist Reprod Genet. 2012; 29(3): 231–236.
  16. Prasad S, Gupta T, Divya A. Correlation of the Day 3 FSH/LH Ratio and LH Concentration in Predicting IVF Outcome. J Reprod Infertil. 2013; 14(1): 23–28.
  17. Kwon SuK, Kim SH, Yun SC, et al. Decline of serum antimüllerian hormone levels after laparoscopic ovarian cystectomy in endometrioma and other benign cysts: a prospective cohort study. Fertil Steril. 2014; 101(2): 435–441.
  18. Ferrero S, Scala C, Tafi E, et al. Impact of large ovarian endometriomas on the response to superovulation for in vitro fertilization: A retrospective study. Eur J Obstet Gynecol Reprod Biol. 2017; 213: 17–21.
  19. Uncu G, Kasapoglu I, Ozerkan K, et al. Prospective assessment of the impact of endometriomas and their removal on ovarian reserve and determinants of the rate of decline in ovarian reserve. Hum Reprod. 2013; 28(8): 2140–2145.
  20. Streuli I, de Ziegler D, Gayet V, et al. In women with endometriosis anti-Müllerian hormone levels are decreased only in those with previous endometrioma surgery. Hum Reprod. 2012; 27(11): 3294–3303.
  21. Roustan A, Perrin J, Debals-Gonthier M, et al. Surgical diminished ovarian reserve after endometrioma cystectomy versus idiopathic DOR: comparison of in vitro fertilization outcome. Hum Reprod. 2015; 30(4): 840–847.
  22. Mohamed KA, Davies WAR, Lashen H. Antimüllerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate. Fertil Steril. 2006; 86(5): 1515–1517.
  23. Orvieto R, Meltzer S, Rabinson J, et al. Does day 3 luteinizing-hormone level predict IVF success in patients undergoing controlled ovarian stimulation with GnRH analogues? Fertil Steril. 2008; 90(4): 1297–1300.
  24. Liu KE, Greenblatt EM. Elevated day 3 follicle-stimulating hormone/luteinizing hormone ratio >or= 2 is associated with higher rates of cancellation in in vitro fertilization-embryo transfer cycles. Fertil Steril. 2008; 90(2): 297–301.
  25. Gomes FM, Navarro PA, de Abreu LG, et al. Effect of peritoneal fluid from patients with minimal/mild endometriosis on progesterone release by human granulosa-lutein cells obtained from infertile patients without endometriosis: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2008; 138(1): 60–65.
  26. Singh AK, Chattopadhyay R, Chakravarty B, et al. Altered circulating levels of matrix metalloproteinases 2 and 9 and their inhibitors and effect of progesterone supplementation in women with endometriosis undergoing in vitro fertilization. Fertil Steril. 2013; 100(1): 127–34.e1.
  27. Karita M, Yamashita Y, Hayashi A, et al. Does advanced-stage endometriosis affect the gene expression of estrogen and progesterone receptors in granulosa cells? Fertil Steril. 2011; 95(3): 889–894.
  28. Lyu SW, Kim JiW, Choi CH, et al. Impact of high basal FSH/LH ratio in women with normal FSH levels on in vitro fertilization outcomes. Gynecol Endocrinol. 2013; 29(5): 424–429.
  29. Kolanska K, Cohen J, Bendifallah S, et al. Pregnancy outcomes after controlled ovarian hyperstimulation in women with endometriosis-associated infertility: GnRH-agonist versus GnRH-antagonist. J Gynecol Obstet Hum Reprod. 2017; 46(9): 681–686.
  30. Vuong TNL, Phung HT, Ho MT. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Hum Reprod. 2015; 30(5): 1188–1195.
  31. Orvieto R, Homburg R, Meltcer S, et al. HMG improves IVF outcome in patients with high basal FSH/LH ratio: a preliminary study. Reprod Biomed Online. 2009; 18(2): 205–208.
  32. Tamura H, Takasaki A, Nakamura Y, et al. A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis. J Ovarian Res. 2014; 7: 100.
  33. Ballester M, Oppenheimer A, d'Argent EM, et al. Nomogram to predict pregnancy rate after ICSI-IVF cycle in patients with endometriosis. Hum Reprod. 2012; 27(2): 451–456.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl